539 related articles for article (PubMed ID: 15872355)
1. Structural requirements for in vivo detection of cell death with 99mTc-annexin V.
Tait JF; Smith C; Blankenberg FG
J Nucl Med; 2005 May; 46(5):807-15. PubMed ID: 15872355
[TBL] [Abstract][Full Text] [Related]
2. Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis.
Ohtsuki K; Akashi K; Aoka Y; Blankenberg FG; Kopiwoda S; Tait JF; Strauss HW
Eur J Nucl Med; 1999 Oct; 26(10):1251-8. PubMed ID: 10541822
[TBL] [Abstract][Full Text] [Related]
3. 99mTc-labeled annexin V fragments: a potential SPECT radiopharmaceutical for imaging cell death.
Mukherjee A; Kothari K; Tóth G; Szemenyei E; Sarma HD; Környei J; Venkatesh M
Nucl Med Biol; 2006 Jul; 33(5):635-43. PubMed ID: 16843838
[TBL] [Abstract][Full Text] [Related]
4. Improved detection of cell death in vivo with annexin V radiolabeled by site-specific methods.
Tait JF; Smith C; Levashova Z; Patel B; Blankenberg FG; Vanderheyden JL
J Nucl Med; 2006 Sep; 47(9):1546-53. PubMed ID: 16954565
[TBL] [Abstract][Full Text] [Related]
5. Detection of apoptotic tumor response in vivo after a single dose of chemotherapy with 99mTc-annexin V.
Mochizuki T; Kuge Y; Zhao S; Tsukamoto E; Hosokawa M; Strauss HW; Blankenberg FG; Tait JF; Tamaki N
J Nucl Med; 2003 Jan; 44(1):92-7. PubMed ID: 12515881
[TBL] [Abstract][Full Text] [Related]
6. Imaging of apoptosis (programmed cell death) with 99mTc annexin V.
Blankenberg FG; Katsikis PD; Tait JF; Davis RE; Naumovski L; Ohtsuki K; Kopiwoda S; Abrams MJ; Strauss HW
J Nucl Med; 1999 Jan; 40(1):184-91. PubMed ID: 9935075
[TBL] [Abstract][Full Text] [Related]
7. 99mTc-Hynic-annexin V imaging to evaluate inflammation and apoptosis in rats with autoimmune myocarditis.
Tokita N; Hasegawa S; Maruyama K; Izumi T; Blankenberg FG; Tait JF; Strauss HW; Nishimura T
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):232-8. PubMed ID: 12552341
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of annexin V mutants with endogenous chelation sites for (99m)Tc.
Tait JF; Brown DS; Gibson DF; Blankenberg FG; Strauss HW
Bioconjug Chem; 2000; 11(6):918-25. PubMed ID: 11087342
[TBL] [Abstract][Full Text] [Related]
9. Time course of Paclitaxel-induced apoptosis in an experimental model of virus-induced breast cancer.
Erba PA; Manfredi C; Lazzeri E; Minichilli F; Pauwels EK; Sbrana A; Strauss HW; Mariani G
J Nucl Med; 2010 May; 51(5):775-81. PubMed ID: 20395330
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of adenosine preconditioning with 99mTc-His10-annexin V in a porcine model of myocardium ischemia and reperfusion injury: preliminary study.
Ye F; Fang W; Wang F; Hua ZC; Wang Z; Yang X
Nucl Med Biol; 2011 May; 38(4):567-74. PubMed ID: 21531294
[TBL] [Abstract][Full Text] [Related]
11. Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application.
Kemerink GJ; Liu X; Kieffer D; Ceyssens S; Mortelmans L; Verbruggen AM; Steinmetz ND; Vanderheyden JL; Green AM; Verbeke K
J Nucl Med; 2003 Jun; 44(6):947-52. PubMed ID: 12791824
[TBL] [Abstract][Full Text] [Related]
12. Optimization of the preparation of 99mTc-labeled Hynic-derivatized Annexin V for human use.
Verbeke K; Kieffer D; Vanderheyden JL; Reutelingsperger C; Steinmetz N; Green A; Verbruggen A
Nucl Med Biol; 2003 Oct; 30(7):771-8. PubMed ID: 14499336
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of 99mTc-MAG3-annexin V: influence of the chelate on in vitro and in vivo properties in mice.
Vanderheyden JL; Liu G; He J; Patel B; Tait JF; Hnatowich DJ
Nucl Med Biol; 2006 Jan; 33(1):135-44. PubMed ID: 16459269
[TBL] [Abstract][Full Text] [Related]
14. In vivo imaging of radiation-induced tissue apoptosis by (99m)Tc(I)-his (6)-annexin A5.
Lin KJ; Wu CC; Pan YH; Chen FH; Fu SY; Chiang CS; Hong JH; Lo JM
Ann Nucl Med; 2012 Apr; 26(3):272-80. PubMed ID: 22278351
[TBL] [Abstract][Full Text] [Related]
15. A simplified method for preparation of 99mTc-annexin V and its biologic evaluation for in vivo imaging of apoptosis after photodynamic therapy.
Subbarayan M; Häfeli UO; Feyes DK; Unnithan J; Emancipator SN; Mukhtar H
J Nucl Med; 2003 Apr; 44(4):650-6. PubMed ID: 12679412
[TBL] [Abstract][Full Text] [Related]
16. Enhanced apoptotic reaction correlates with suppressed tumor glucose utilization after cytotoxic chemotherapy: use of 99mTc-Annexin V, 18F-FDG, and histologic evaluation.
Takei T; Kuge Y; Zhao S; Sato M; Strauss HW; Blankenberg FG; Tait JF; Tamaki N
J Nucl Med; 2005 May; 46(5):794-9. PubMed ID: 15872353
[TBL] [Abstract][Full Text] [Related]
17. Study of 99mTc-annexin V uptake in apoptotic cell models of Parkinson's disease.
Cao W; Huang J; Wu J; Cao G; He Y; Hu D; Sun S; An R; Zhang Y
Nucl Med Commun; 2007 Dec; 28(12):895-901. PubMed ID: 18090214
[TBL] [Abstract][Full Text] [Related]
18. Apoptotic abscess imaging with 99mTc-HYNIC-rh-Annexin-V.
Penn DL; Kim C; Zhang K; Mukherjee A; Devakumar D; Jungkind D; Thakur ML
Nucl Med Biol; 2010 Jan; 37(1):29-34. PubMed ID: 20122665
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis.
Yagle KJ; Eary JF; Tait JF; Grierson JR; Link JM; Lewellen B; Gibson DF; Krohn KA
J Nucl Med; 2005 Apr; 46(4):658-66. PubMed ID: 15809489
[TBL] [Abstract][Full Text] [Related]
20. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
